NCT02337868View on ClinicalTrials.gov

Phase 1 Trial of Inactivated West Nile Virus Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

December 16, 2016

Study Completion Date

December 16, 2016

Conditions
West Nile Viral Infection
Interventions
BIOLOGICAL

HydroVax-001

HydroVax-001 West Nile Virus inactivated vaccine, alum-adsorbed given at doses of 1 mcg (low dose) and 4 mcg (high dose) IM on days 1 and 29

OTHER

Placebo

0.9% Sodium Chloride Injection diluent will be given IM on days 1 and 29

Trial Locations (1)

27704

Duke Human Vaccine Institute - Duke Clinical Vaccine Unit, Durham

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02337868 - Phase 1 Trial of Inactivated West Nile Virus Vaccine | Biotech Hunter | Biotech Hunter